342
Participants
Start Date
October 13, 2014
Primary Completion Date
May 3, 2018
Study Completion Date
May 3, 2018
Paclitaxel
Carboplatin
Ipilimumab
Placebo
0.9% sodium chloride injection, USP, or 5% dextrose injection
Pulmonologiai Klinika, Budapest
Torokbalinti Tudogyogyintezet, Törökbálint
Csongrad Megyei Onkormanyzat Mellkasi Betegsegek Szakkorhaza, Deszk
Local Institution, Berlin
Local Institution, Suwon
Local Institution, Hamburg
Local Institution, Cheongju-si
Local Institution, Mainz
Local Institution, Hwasun-gun
Local Institution, Löwenstein
Local Institution, Beijing
Local Institution, Beijing
Local Institution, Beijing
Local Institution, Changchun
Local Institution, Changchun
Local Institution, Singapore
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution, Shanghai
Local Institution, Nanjing
Local Institution, Nanjing
Local Institution, Singapore
Local Institution, Hangzhou
Local Institution, Hangzhou
Local Institution, Hangzhou
Local Institution, Hangzhou
Local Institution, Fuzhou
Local Institution, Chongqing
Local Institution, Chongqing
Local Institution, Changsha
Local Institution, Guangzhou
Local Institution, Guangzhou
Local Institution, Guangzhou
Local Institution, Shantou
Local Institution, Chengdu
Local Institution, Xi'an
Local Institution, Xi'an
Local Institution, Zhengzhou
Local Institution, Changsha
Local Institution, Fuzhou
Local Institution, Kunming
Local Institution, Halle
Local Institution, Leipzig
Oddzial Onkologiczny, Elblag
Oddzial Chemioterapii, Poznan
Klinika Nowotworow Pluca i Klatki Piersiowej, Warsaw
Local Institution, Seoul
Local Institution, Seoul
Local Institution, Seoul
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY